Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-2 receptor subunit gamma (IL2RG), also known as the common gamma chain (gamma-c) or CD132, is a vital type I cytokine receptor subunit shared by the receptor complexes of at least six interleukins: IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. It is constitutively expressed on most lymphocyte populations, including T cells, B cells, and natural killer (NK) cells, where it plays an indispensable role in lymphocyte development, survival, and immune homeostasis. Upon cytokine binding, IL2RG associates with cytokine-specific receptor subunits and activates downstream signaling cascades, primarily via the Janus kinase 3 (JAK3) and signal transducer and activator of transcription 5 (STAT5) pathways. Mutations in the IL2RG gene lead to X-linked severe combined immunodeficiency (X-SCID), a life-threatening condition characterized by a profound lack of functional T, B, and NK cells. In therapeutic contexts, IL2RG is targeted by both agonists and antagonists; IL2RG-dependent cytokine agonists (such as aldesleukin and IL-15 superagonists) are utilized in cancer immunotherapy to boost anti-tumor immune responses, whereas IL2RG antagonists and multi-cytokine inhibitors (such as REGN7257 and EQ101) are being developed to treat autoimmune disorders, transplant rejection, and T-cell malignancies by suppressing aberrant immune activation.
Inhibition of common gamma chain (CD132) cytokine signaling to suppress T-cell and NK-cell activation; Activation of the IL-2/IL-15 receptor complex to stimulate cytotoxic immune responses.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-2 receptor subunit gamma (IL2RG).